High Prevalence of TP53 Loss and Whole-genome Doubling in Early-onset Colorectal Cancer
Overview
Molecular Biology
Authors
Affiliations
The global incidence of early-onset colorectal cancer (EO-CRC) is rapidly rising. However, the reason for this rise in incidence as well as the genomic characteristics of EO-CRC remain largely unknown. We performed whole-exome sequencing in 47 cases of EO-CRC and targeted deep sequencing in 833 cases of CRC. Mutational profiles of EO-CRC were compared with previously published large-scale studies. EO-CRC and The Cancer Genome Atlas (TCGA) data were further investigated according to copy number profiles and mutation timing. We classified colorectal cancer into three subgroups: the hypermutated group consisted of mutations in POLE and mismatch repair genes; the whole-genome doubling group had early functional loss of TP53 that led to whole-genome doubling and focal oncogene amplification; the genome-stable group had mutations in APC and KRAS, similar to conventional colon cancer. Among non-hypermutated samples, whole-genome doubling was more prevalent in early-onset than in late-onset disease (54% vs 38%, Fisher's exact P = 0.04). More than half of non-hypermutated EO-CRC cases involved early TP53 mutation and whole-genome doubling, which led to notable differences in mutation frequencies between age groups. Alternative carcinogenesis involving genomic instability via loss of TP53 may be related to the rise in EO-CRC.
Geographic and age-related variations in mutational processes in colorectal cancer.
Diaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele C medRxiv. 2025; .
PMID: 40034755 PMC: 11875255. DOI: 10.1101/2025.02.13.25322219.
The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.
Hertel A, Storchova Z Biomolecules. 2025; 15(2).
PMID: 40001547 PMC: 11852650. DOI: 10.3390/biom15020244.
Hamilton A, Bannon F, Dunne P, James J, McQuaid S, Gray R Gastro Hep Adv. 2024; 2(3):347-359.
PMID: 39132649 PMC: 11307521. DOI: 10.1016/j.gastha.2022.11.005.
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.
Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y Signal Transduct Target Ther. 2024; 9(1):149.
PMID: 38890350 PMC: 11189549. DOI: 10.1038/s41392-024-01848-7.
Tang J, Peng W, Tian C, Zhang Y, Ji D, Wang L Int J Surg. 2024; 110(8):4559-4570.
PMID: 38742845 PMC: 11326018. DOI: 10.1097/JS9.0000000000001584.